High Growth Tech Stocks in US Market with Promising Potential

Why Serviceware SE (ETR:SJJ) Could Be Worth Watching

As the U.S. market experiences slight gains, with the Dow Jones and S&P 500 inching higher amid anticipation for Nvidia’s earnings report, investors are closely monitoring developments that could impact broader market sentiment. In such a dynamic environment, identifying high growth tech stocks requires careful consideration of their adaptability to current economic conditions and potential to leverage technological advancements effectively.

Name

Revenue Growth

Earnings Growth

Growth Rating

ACADIA Pharmaceuticals

10.87%

25.66%

★★★★★☆

ADMA Biologics

20.60%

23.25%

★★★★★☆

Palantir Technologies

25.17%

31.57%

★★★★★★

Workday

11.57%

30.09%

★★★★★☆

OS Therapies

57.14%

70.11%

★★★★★☆

RenovoRx

65.52%

68.83%

★★★★★☆

Circle Internet Group

27.36%

78.79%

★★★★★☆

Vanda Pharmaceuticals

22.66%

59.11%

★★★★★☆

Gorilla Technology Group

27.68%

129.58%

★★★★★☆

Aldeyra Therapeutics

42.88%

74.81%

★★★★★☆

Click here to see the full list of 67 stocks from our US High Growth Tech and AI Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Simply Wall St Growth Rating: ★★★★★☆

Overview: ADMA Biologics, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and marketing specialty plasma-derived biologics for treating immune deficiencies and infectious diseases globally, with a market cap of $4.06 billion.

Operations: The company generates revenue primarily from its ADMA Biomanufacturing segment, which accounts for $465.17 million, while its Plasma Collection Centers contribute $8.86 million.

ADMA Biologics showcases robust growth with a projected annual revenue increase of 20.6% and earnings expected to surge by 23.3% per year, outpacing the US market averages significantly. The company’s recent financial performance underscores this trajectory, reporting a substantial year-over-year earnings growth of 500.6%, dwarfing its industry’s average. In tandem with financial growth, ADMA has committed to expanding its capabilities through strategic investments in R&D, evidenced by their latest credit agreement for $300 million aimed at bolstering their operational and developmental endeavors. This approach not only secures ADMA’s position in biotech innovation but also enhances its competitive edge in a rapidly evolving sector.

ADMA Revenue and Expenses Breakdown as at Aug 2025

Simply Wall St Growth Rating: ★★★★★☆

Overview: Cellebrite DI Ltd. provides solutions for legally sanctioned investigations across various regions including Europe, the Middle East, Africa, the Americas, and the Asia-Pacific with a market cap of $3.87 billion.

Source link

Visited 1 times, 1 visit(s) today

Leave a Reply

Your email address will not be published. Required fields are marked *